Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial

<p>BACKGROUND: Up to 60% of patients with Crohn's disease need intestinal resection within the first 10 years of diagnosis, and postoperative recurrence is common. We investigated whether mercaptopurine can prevent or delay postoperative clinical recurrence of Crohn's disease.</p&...

Full description

Bibliographic Details
Main Authors:	Mowat, C, Arnott, I, Cahill, A, Smith, M, Ahmad, T, Subramanian, S, Travis, S, Morris, J, Hamlin, J, Dhar, A, Nwokolo, C, Edwards, C, Creed, T, Bloom, S, Yousif, M, Thomas, L, Campbell, S, Lewis, S, Sebastian, S, Sen, S, Lal, S, Hawkey, C, Murray, C, Cummings, F, Goh, J, Lindsay, J, Arebi, N, Potts, L, McKinley, A, Thomson, J, Todd, J, Collie, M, Dunlop, M, Mowat, A, Gaya, D, Winter, J, Naismith, G, Ennis, H, Keerie, C, Prescott, R, Kennedy, N, Satsangi, J, TOPPIC Study Group
Format:	Journal article
Language:	English
Published:	Elsevier 2016

Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial

Similar Items